Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

The recent initiation of first patient dosing marks a significant advancement for IHL-42X, following promising Phase 2 RePOSA outcomes showing reductions in Apnea-Hypopnea Index (AHI) by as much as 83%. Additionally, the FDA has granted Fast Track designation to this innovative treatment. This achievement underscores the potential efficacy of IHL-42X in addressing sleep-related disorders and highlights its progress in clinical development.